Sunday, January 07, 2024 10:08:51 PM
Many of mine have crossed the Rubicon the last 3 years, and BIXT will be one of the next ones this year. I hear they are recruiting folks for first of two parts of the Phase III in India already, the dosing trial, to set the dose for second part of the phase III.
Lots of other catalysts brewing already.
Holy Cow who said sugar molecules were baaaahhhdASS LOL
$BIXT Galectin Antagonists (antiviral molecules) Designed by AI, and could IMO end the need for many vaccines... Already has 2 Phase III trials in two countries ready:
Viruses trigger Neurological diseases published research is out:
BIXT can stop the virus:
Why BIXT?
https://www.cell.com/neuron/fulltext/S0896-6273(22)01147-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627322011473%3Fshowall%3Dtrue
https://www.dailystar.co.uk/news/latest-news/covid-morphed-stomach-bug-experts-31737142
Lots of other catalysts brewing already.
Holy Cow who said sugar molecules were baaaahhhdASS LOL
$BIXT Galectin Antagonists (antiviral molecules) Designed by AI, and could IMO end the need for many vaccines... Already has 2 Phase III trials in two countries ready:
Viruses trigger Neurological diseases published research is out:
BIXT can stop the virus:
Why BIXT?
https://www.cell.com/neuron/fulltext/S0896-6273(22)01147-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627322011473%3Fshowall%3Dtrue
https://www.dailystar.co.uk/news/latest-news/covid-morphed-stomach-bug-experts-31737142
Bullish
Recent BIXT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 05:28:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:01:16 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 10:23:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 01:05:14 PM
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT • GlobeNewswire Inc. • 03/20/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:00:24 PM
- Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M • GlobeNewswire Inc. • 03/04/2026 08:40:00 PM
- Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 • ACCESS Newswire • 03/02/2026 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 02:22:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 11:20:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 11:04:17 AM
- Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran • GlobeNewswire Inc. • 02/11/2026 11:00:00 AM
- Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics • GlobeNewswire Inc. • 02/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 10:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 11:15:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:02:52 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/18/2025 06:12:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:00:57 PM
- Bioxytran Announces Initiation of Coverage of its Stock by Independent Research • GlobeNewswire Inc. • 11/13/2025 06:50:00 PM
- Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug • GlobeNewswire Inc. • 10/29/2025 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2025 11:01:03 AM
